Fig. 2. bNAb plasma concentrations do not differ between treatment groups before viral rebound.

(A) Shown are the plasma concentrations (means ± SD) of anti–HIV bNAbs VRC07–523LS and PGT128 6 days before the first detection of >200 copies/ml of SHIV RNA in the bNAbs-only and bNAbs–Rh-α₄β₇ treatment groups. (B) Shown are the medians ± range of CD4⁺ T cell counts in blood for different time points after SHIV infection in the three groups of animals. Differences between groups were tested at each time point by Kruskal-Wallis test, and differences between time points were tested with a mixed-effect analysis using Geisser-Greenhouse correction and Tukey’s multiple comparisons test. *P < 0.05 and **P < 0.01.